Malarone (Proguanil Hydrochloride, Atovaquone)

Malarone is an antiprotozoal used in malaria prevention and treatment.

• Prevention of malaria infection: provides prophylactic protection for travelers and residents in endemic regions.
• Treatment of acute uncomplicated malaria caused by Plasmodium species: clears parasitemia and resolves clinical symptoms.
• Chemoprophylaxis for chloroquine‑resistant malaria: offers an alternative regimen where other prophylactics are ineffective.

• Atovaquone interferes with the mitochondrial electron transport chain of Plasmodium parasites, halting ATP synthesis, while proguanil is metabolised to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme. The combined action results in synergistic disruption of nucleic acid synthesis and energy production, leading to parasite death.

Malarone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: transient cranial discomfort.
• Abdominal pain: cramp-like discomfort in the abdomen.
• Vomiting: occasional expulsion of stomach contents.

Serious or Rare Side Effects

• Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic enzyme elevation: potential liver function abnormalities.
• Hemolytic anemia in G6PD deficiency: breakdown of red blood cells.
• Anaphylaxis: life‑threatening allergic response.

Before prescribing Malarone, consider the following precautions to ensure safe use.

• Pregnancy: safety not established; use only if potential benefit justifies the risk.
• Breastfeeding: unknown effects on the infant; weigh risks versus benefits.
• Renal impairment: dose adjustment may be required in severe kidney dysfunction.
• Hepatic impairment: use with caution in patients with liver disease.
• Drug resistance: ensure adherence to the full regimen to prevent resistance development.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Malarone can interact with several medicines; awareness of major and moderate interactions helps manage therapy.

Major Interactions (Avoid)

• Rifampin: markedly reduces atovaquone plasma concentrations, compromising efficacy.
• Cimetidine: may increase atovaquone levels, raising risk of toxicity.
• Protease inhibitors (e.g., ritonavir): can alter metabolism of both components.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: decrease atovaquone absorption; separate dosing by at least 2 hours.
• Warfarin: potential alteration of INR; monitor coagulation parameters.
• Statins (e.g., simvastatin): increased risk of myopathy; observe for muscle symptoms.